Pfizer hires Novartis oncology exec to steer its cancer ambitionsnews2025-02-06T14:48:12+00:00February 6th, 2025|Endpoints News|
AstraZeneca offers some detail on China probe, reaffirms commitment to that marketnews2025-02-06T12:36:59+00:00February 6th, 2025|Endpoints News|
Lilly posts 45% sales jump, culls four programs across obesity, Alzheimer’s, heart failure and eczemanews2025-02-06T12:34:03+00:00February 6th, 2025|Endpoints News|
Bristol Myers launches new round of major cost cutsnews2025-02-06T11:59:48+00:00February 6th, 2025|Endpoints News|
Novo Nordisk is feeling the competition from compounded GLP-1s, exec saysnews2025-02-05T19:33:53+00:00February 5th, 2025|Endpoints News|
Revance, Crown near deal close after earlier bidding warnews2025-02-05T18:42:58+00:00February 5th, 2025|Endpoints News|
EyePoint shares more mid-stage data for therapy trying to compete with Regeneron’s Eyleanews2025-02-05T16:15:01+00:00February 5th, 2025|Endpoints News|
GSK defiant against vaccine challenges, will prioritize other growth areasnews2025-02-05T12:21:44+00:00February 5th, 2025|Endpoints News|
Updated: Novo Nordisk sees growth slowing this year, plans CagriSema filing for 2026news2025-02-05T11:33:08+00:00February 5th, 2025|Endpoints News|
Amgen announces hold on Phase 1 obesity candidate, pipeline cutsnews2025-02-05T01:51:23+00:00February 5th, 2025|Endpoints News|
